Gabapentin (All indications)

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15270
R62757		 Desrochers, 2022 Cardiac malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.29 [0.72;2.31] -/-   -/288,357 - -
ref
S8491
R35398		 Miškov (Controls unexposed, disease free), 2016 Congenital heart defect during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 765.00 [11.05;52971.87] C
excluded (control group) 		1/2   0/128 1 2
ref
S8492
R35405		 Miškov (Controls unexposed, sick), 2016 Congenital heart defect during pregnancy (anytime or not specified) excluded prospective cohort unexposed, sick Adjustment: No 21.00 [0.27;1646.32] C
excluded (exposition period) 		1/2   0/4 1 2
ref
S8493
R27900		 Morrow (Controls exposed to Lamotrigine, sick), 2006 Cardiac 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 5.36 [0.58;49.42] C 1/31   4/647 5 31
ref
Total 2 studies 1.73 [0.56;5.33] 5 31
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Desrochers, 2022Desrochers, 2022 1.29[0.72; 2.31]--80%ROB confusion: unclearROB selection: unclearROB classification: unclearROB missing: unclearROB mesure: unclearROB reporting: moderate Morrow (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 1 5.36[0.58; 49.42]53120%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 32% 1.73[0.56; 5.33]5310.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.73[0.56; 5.33]53132%NADesrochers, 2022 Morrow (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.29[0.72; 2.31]-- -NADesrochers, 2022 1 exposed to other treatment, sickexposed to other treatment, sick 5.36[0.58; 49.42]531 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 5.36[0.58; 49.42]531 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1   - Yes  - Yes 1.29[0.72; 2.31]-- -NADesrochers, 2022 1 All studiesAll studies 1.73[0.56; 5.33]53132%NADesrochers, 2022 Morrow (Controls exposed to Lamotrigine, sick), 2006 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8491

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.29[0.72; 2.31]-- -NADesrochers, 2022 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 5.36[0.58; 49.42]531 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 10.510.01.0